
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 5, 2026, 2:37 PM ET
RBC Capital lifts GRAIL price target to $100 from $84
U.S. listed: $GRALCancer screening and diagnosticsExecution and funding risks
GRAL Stock Hub: GRAIL News, Cancer Screening and Galleri
GRAIL reported Q3 revenue of $37.5 million, including $37.3 million from Galleri. September 30 liquidity was $788.7 million. GRAIL anticipates an FDA decision on Galleri by early Q1 2027.
Full research report · PDF
GRAIL research updated November 5, 2026
20 pages. Q3 financial results, Galleri clinical evidence, the FDA advisory votes, liquidity and dilution. Personal use only: redistribution prohibited.
Next company milestone
By early Q1 2027 · FDA decision on Galleri
A management presentation at the UBS Global Healthcare Conference in Palm Beach, Florida, was set for November 10, and Q3 results were released on November 4. The company anticipates an FDA decision on Galleri by early Q1 2027; that is a company expectation, not a fixed FDA action date. UBS presentation announcement; Q3 2026 results
Company-guided windows remain forecasts; completed events are dated separately from the next operating or financial disclosure.
GRAL stock at a glance
Chart analysis · JC
Technical chart analysis of $GRAL with bull and bear scenarios on JC Just Charts.
Common shares
44.962M
Outstanding on November 2, 2026 (Form 10-Q cover); 44.753M at September 30.
SourceWhere GRAIL stands now
GRAIL reported Q3 revenue of $37.5 million, including $37.3 million from Galleri. September 30 liquidity was $788.7 million. GRAIL anticipates an FDA decision on Galleri by early Q1 2027. On September 23, 2026, the FDA advisory panel voted on Galleri for the proposed screening population of adults aged 50 and older. On whether the data reasonably supported safety, the vote was 10 yes, 0 no and 0 abstentions. On effectiveness, it was 6 yes, 4 no and 0 abstentions. On whether benefits outweighed risks, it was 7 yes, 2 no and 1 abstention. FDA makes the final decision. FDA voting summary.
Q3 total revenue was $37.535 million versus $36.194 million a year earlier. Galleri revenue was $37.269 million, up 14%, on more than 56,000 tests, up approximately 24%. Development services contributed $0.266 million. Nine-month revenue was $123.007 million versus $103.575 million, including $119.743 million of Galleri revenue, up 24%, on more than 174,000 tests, up 36%. GAAP net loss was $103.568 million for Q3 and $307.002 million for nine months. GAAP Q3 gross loss was $18.111 million. Q3 income statement.
Execution and funding. The NHS combined stage III/IV primary endpoint was missed. A restrictive or delayed regulatory outcome, weak repeat adoption or persistent cash consumption could outweigh the favorable panel vote. A large cash balance does not guarantee per-share value or prevent further dilution. [FDA] [Q]
The constructive case
A favorable final label, manageable study obligations, growing repeat use and meaningful coverage could turn an already commercial screening platform into a larger recurring business. Liquidity of $788.7 million at September 30 gives GRAIL resources to pursue that transition. Approval, reimbursement and cash generation remain separate milestones.
The cautious case
The NHS combined stage III/IV primary endpoint was missed. In Q3 2026 the net loss widened to $103.6 million from $89.0 million a year earlier, and adjusted gross margin fell to 42% from 55%. A restrictive or delayed regulatory outcome, weak repeat adoption or persistent cash consumption could outweigh the favorable panel vote. A large cash balance does not guarantee per-share value or prevent further dilution. [FDA] [Q]
Latest GRAIL news
Nov 5, 2026
RBC Capital lifts GRAIL price target to $100 from $84
RBC Capital raised its price target on GRAIL to $100 from $84. The bank kept its Sector Perform rating on the stock. Analyst action reported by the press; it is the bank's view, not Merlintrader's.
Nov 4, 2026
GRAIL Reports Third Quarter 2026 Financial Results
Galleri test revenue for the third quarter grew 14% year-over-year to $37.3 million, and total revenue grew 4% year-over-year to $37.5 million. Galleri test volume grew approximately 24% year-over-year to more than 56,000 tests. Net loss for the third quarter was $103.6 million, and non-GAAP adjusted EBITDA was $(92.6) million. Cash, cash equivalents, and short-term marketable securities totaled $788.7 million as of September 30, 2026.
Nov 3, 2026
Chancery court ends Icahn lawsuit over Illumina's $8B acquisition of Grail
A Chancery court has ended the lawsuit brought by Icahn over Illumina's $8B deal for Grail. The source gives no further details. Not confirmed by a company release or filing at the time of writing; to be verified.
Nov 3, 2026
FDA panel backs GRAIL's cancer detection test
An FDA panel backed GRAIL's cancer detection test. No further details are given in the available headline. Not confirmed by a company release or filing at the time of writing; to be verified.
Oct 27, 2026
UBS conference scheduled for November 10
The company calendar lists the UBS Global Healthcare Conference on November 10 at 11:00 am ET. This is a scheduled investor event, separate from the November 4 financial results and from any final FDA decision.
Oct 21, 2026
Q3 results date set for November 4
GRAIL will report third-quarter 2026 results after the market close on Wednesday, November 4, 2026, followed by a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET.
GRAL stock catalysts and company milestones
- October 27 PATHFINDER 2 subgroup analysis Completed
- October 26 ESMO PATHFINDER 2 Completed
- October 25 ESMO claims analysis Completed
- November 4, 2026 — Q3 2026 results released after the close (total revenue $37.5 million, net loss $103.6 million), followed by a 4:30 pm ET call. Completed
- November 10, 2026 · 11:00 am ET — Presentation at the UBS Global Healthcare Conference in Palm Beach, Florida, was set for this date. Company-announced event
- By early Q1 2027 — FDA decision on Galleri anticipated by the company. Company expectation; no fixed FDA action date
Q3 2026 results; UBS presentation announcement; Company event calendar
Business model: a screening service with a long evidence cycle
GRAIL, Inc. is a cancer-detection company listed on Nasdaq under GRAL. Its central commercial asset is Galleri, a prescription blood test designed to look for a cancer-associated signal across multiple cancer types and, when a signal is detected, indicate a likely anatomical origin. The company’s September and October 2026 communications identify Sunnyvale, California, as its headquarters. The June-quarter 10-Q cover still shows Menlo Park, although the filing notes that the new Sunnyvale headquarters became available on June 1, 2026. The product is a screening service, not a cancer treatment and not a definitive diagnosis. [FDA] [Q] [O]
The business can be understood as a sequence of linked transactions. A healthcare professional orders a test; a sample is collected and shipped; GRAIL processes it and delivers a result; a positive result requires a diagnostic pathway outside the assay itself. Revenue from the screening test therefore measures only one part of the wider healthcare intervention. The laboratory’s commercial success depends on whether patients, clinicians and payers find the entire pathway useful enough to repeat and fund.
Financial statements: liquidity is not profitability
At June 30, 2026, GRAIL reported $55.645 million in cash and cash equivalents and $805.964 million in short-term marketable securities. Their sum is $861.609 million. Restricted cash of $6.974 million is separate and is not added to the readily available liquidity figure shown above. These figures are dated June 30. [Q]
For Q2, the company reported an operating loss of $173.783 million and a net loss of $110.247 million. GAAP gross loss was $12.566 million. Adjusted gross profit of $21.555 million excludes specified items, including amortization and allocated stock compensation, and is therefore not the same metric. Adjusted EBITDA was negative $90.270 million. Presenting the adjusted gross figure without the GAAP loss would make the business look more mature than its reported accounts. [Q]
Q3 total revenue was $37.535 million versus $36.194 million a year earlier. Galleri revenue was $37.269 million, up 14%, on more than 56,000 tests, up approximately 24%. Development services contributed $0.266 million. Nine-month revenue was $123.007 million versus $103.575 million, including $119.743 million of Galleri revenue, up 24%, on more than 174,000 tests, up 36%. GAAP net loss was $103.568 million for Q3 and $307.002 million for nine months. GAAP Q3 gross loss was $18.111 million. Q3 income statement.
Q3 adjusted gross profit was $15.914 million and adjusted gross margin was 42%, versus $20.011 million and 55% a year earlier. GRAIL excludes intangible amortization and stock-based compensation allocated to cost of revenue. Adjusted EBITDA was a loss of $92.580 million versus $71.704 million a year earlier. GRAIL adjusts net loss for intangible amortization, stock compensation, depreciation, impairment, income tax benefit, interest income and restructuring. Company reconciliations.
At September 30, 2026, cash and equivalents were $28.976 million and short-term marketable securities were $759.700 million, for $788.676 million in combined liquidity. Restricted cash of $6.943 million was separate. The condensed balance sheet listed $85.848 million in current and non-current operating lease liabilities and showed no separate debt or convertible-debt line. Q3 balance sheet.
The Form 10-Q filed on November 5 covers the first nine months of 2026: net cash used in operating activities was $242.459 million, against $235.222 million a year earlier, and financing activities provided $113.981 million, mainly the $109.0 million of net proceeds from the June Samsung share purchase. GRAIL states that existing cash, cash equivalents and short-term marketable securities, together with the anticipated commercial adoption of Galleri, will be sufficient for at least the next 12 months from the filing date. Q3 2026 Form 10-Q and November 4 Q3 release.
GRAIL reported 44,753,179 common shares issued and outstanding on September 30 in its Q3 balance sheet, compared with 44,666,234 at June 30 and 40,331,360 at December 31, 2025; the Form 10-Q cover reports 44,962,171 shares on November 2, 2026. At September 30, $189.3 million of shares remained available under the ATM program, unchanged from June 30. Available capacity can fund operations through new share issuance and can dilute existing ownership. September balance sheet and Q3 2026 Form 10-Q.
Merlintrader Health Score · $GRAL
3.10out of 5
Reassessed November 5, 2026, including the Form 10-Q filed that day; scores unchanged. Weighted calculation: (3.5 × 30%) + (3.0 × 30%) + (2.5 × 20%) + (3.5 × 10%) + (3.0 × 10%) = 3.10 / 5. Financial and operating resilience over twelve to eighteen months; no price target or investment recommendation.
Red flags
- The NHS combined stage III/IV primary endpoint was missed. A restrictive or delayed regulatory outcome, weak repeat adoption or persistent cash consumption could outweigh the favorable panel vote. A large cash balance does not guarantee per-share value or prevent further dilution. [FDA] [Q]
- Company forecasts depend on execution and may change.
- Financing after September 30 would change liquidity and could increase the share count.
- Investment involves possible loss of part or all of the capital.
GRAL Stock FAQ: GRAIL Questions Answered
What is the next GRAL stock catalyst?
As of November 11, 2026, GRAIL’s next catalyst is the FDA decision on Galleri, which the company anticipates by early Q1 2027; that is a company expectation, not a fixed FDA action date. A presentation at the UBS Global Healthcare Conference was set for November 10, 2026. GRAIL released Q3 results after the November 4 regular-session close. The FDA has the final decision. Q3 release and Company event announcement.
Is the GRAIL Galleri test FDA approved?
The FDA decision on Galleri was pending as of November 5, 2026. On September 23, 2026, the FDA advisory panel voted on Galleri for the proposed screening population of adults aged 50 and older. On whether the data reasonably supported safety, the vote was 10 yes, 0 no and 0 abstentions. On effectiveness, it was 6 yes, 4 no and 0 abstentions. On whether benefits outweighed risks, it was 7 yes, 2 no and 1 abstention. FDA makes the final decision. FDA voting summary.
How much cash does GRAIL have?
GRAIL held $788.676 million in cash, cash equivalents and short-term marketable securities at September 30, 2026, down from $861.609 million at June 30, 2026. September balance sheet. June balance sheet and cash flows.
Could GRAIL issue more GRAL shares?
GRAIL could issue more shares under the ATM program, which had $189.3 million of capacity remaining at June 30, 2026. Common shares outstanding increased to 44,753,179 at September 30 from 44,666,234 at June 30. June Form 10-Q and September balance sheet.
When does GRAIL next report earnings?
As of November 11, 2026, GRAIL has not announced its next earnings date. On November 4, 2026, it reported $37.5 million in Q3 revenue and a $103.6 million GAAP net loss after the close. Galleri revenue grew 14% year over year to $37.3 million on more than 56,000 tests. Q3 financial results.
What does GRAIL do?
As of November 4, 2026, GRAIL sold a prescription blood test that screens for cancer signals. Galleri looks for cancer-associated DNA methylation and can suggest where to investigate a detected signal. Company description and Galleri information.
Did the GRAIL NHS-Galleri trial meet its primary endpoint?
The NHS-Galleri trial missed its combined stage III and IV primary endpoint, as reported on May 30, 2026. The published incidence rate ratio for stage IV alone after three screening rounds was 0.86, a key secondary result. Original NHS-Galleri trial.
Does a positive GRAIL Galleri result diagnose cancer?
The FDA advisory panel stated on September 23, 2026 that a positive Galleri test requires further diagnostic work to confirm cancer. A negative test cannot rule out cancer. The FDA panel advised patients to continue guideline-recommended screening. FDA panel summary.
Primary sources
- November 5, 2026 — Form 10-Q for the quarter ended September 30, 2026: nine-month cash flows, ATM capacity and 44,962,171 shares on November 2
- November 4, 2026 — Q3 2026 results, balance sheet and FDA decision timing (Form 8-K, Exhibit 99.1)
- FDA · executive summary
- SEC Form 10-Q · June 30, 2026
- FDA · Galleri panel presentation
- FDA · September 23 voting summary
- GRAIL · September 23, 2026
- GRAIL · October 5, 2026 conference announcement
- NCI · multi-cancer screening questions
- GRAIL · NHS-Galleri results, May 30, 2026
- GRAIL · PATHFINDER 2, May 31, 2026
- EDCC · official conference dates
- ESMO · Congress 2026 official dates
- GRAIL · Q2 results, August 5, 2026
- GRAIL · Samsung financing, June 25, 2026
- GRAIL · leadership and board
- SEC Schedule 13G/A · Farallon, August 13, 2026
- SEC Form 4 · Aaron Freidin, September 23, 2026
- SEC Form 4 · Joshua Ofman, September 23, 2026
- GRAIL · analyst coverage
- Abbott · Exact Sciences acquisition completed
- SEC Form 144 · Aaron Freidin, October 5, 2026
- SEC Form 144 · Andrew Partridge, October 5, 2026
- SEC Form 3 · Andrew Partridge, Chief Growth Officer, June 2026
- Guardant Health · Shield FDA approval, July 29, 2024 (SEC Form 8-K, Ex. 99.1)
- October 21, 2026 — Q3 results date set for November 4
- October 16, 2026 — CEO Ofman sells 20,000 shares under a 10b5-1 plan
- October 5, 2026 — scientific program
- September 23, 2026 — favorable advisory vote
- August 5–6, 2026 — Q2 results and Form 10-Q
- August 13, 2026 — SEC Schedule 13G/A · Farallon, August 13, 2026
- October 27, 2026 — UBS conference scheduled for November 10
- NHS-Galleri randomized trial · September 22, 2026
- NHS-Galleri results by screening round
- ESMO claims analysis · October 25, 2026
- ESMO PATHFINDER 2 · October 26, 2026
- PATHFINDER 2 age 65 and older · October 27, 2026
Disclaimer. Educational and informational commentary only. This is not investment advice or a recommendation to buy, sell or hold a security. AI-assisted analysis uses dated primary disclosures; errors remain possible and company forecasts are not guarantees. Verify material facts in the sources.
Cancer-screening studies, regulatory decisions, diagnostic follow-up, reimbursement and financing carry risks. A test signal is not a cancer diagnosis, and a negative test does not exclude cancer or replace recommended screening. Investments may lose substantial value.



